MonoGen Pharmaceuticals

MonoGen Pharmaceuticals appears to have been a small oncology-focused biotechnology company co-founded by David J. Bearss to develop drug candidates discovered in academic cancer research. Publicly available information on the company is sparse, but multiple sources indicate Bearss later sold MonoGen before joining SuperGen, and a separate biography states the company founded by Bearss and acquired by SuperGen in 2006 was Montigen Pharmaceuticals, suggesting possible source confusion between MonoGen and Montigen. Because of that ambiguity, MonoGen Pharmaceuticals is best treated as a historical, likely inactive early-stage biotech entity rather than a well-documented standalone operating company. No reliable current evidence was found of an active website, current pipeline, public listing, or ongoing operations under the MonoGen Pharmaceuticals name.